Today: 19 April 2026
Corning stock steadies before U.S. open after JPMorgan sticks with Overweight, insider sale disclosed
3 February 2026
1 min read

Corning stock steadies before U.S. open after JPMorgan sticks with Overweight, insider sale disclosed

New York, Feb 3, 2026, 07:00 EST — Premarket

  • Corning shares showed little movement early Tuesday, following a sharp nearly 7% rise in the prior session.
  • JPMorgan stuck with its Overweight rating, highlighting stronger trends in LCD panel prices.
  • An SEC filing revealed that retired president Eric Musser offloaded 25,000 Corning shares on Monday.

Corning Incorporated’s stock held near $110.36 in early trading Tuesday, following a sharp 6.9% gain that pushed it to $110.36 at Monday’s close.

JPMorgan has reiterated its Overweight rating on the stock and maintained a $115 price target, signaling confidence that the shares will outperform. The bank noted that panel area shipments in December exceeded typical seasonal trends, while panel prices rose in January with further hikes anticipated in February. However, it cautioned that rising TV prices might still dampen unit demand.

Data centers remain a hot topic. In a Tuesday report, Optica’s OPN magazine spotlighted Corning’s multi-year deal with Meta, valued at up to $6 billion. Meta executive Joel Kaplan emphasized that advanced U.S. data centers “require world-class partners,” while Corning CEO Wendell Weeks said the partnership boosts domestic supply chains. optica-opn.org

On Monday, retired president Eric S. Musser unloaded 25,000 Corning shares at a weighted average price of $110.0032, according to a Form 4 filed with the U.S. Securities and Exchange Commission. That sale leaves him holding 19,926 shares. Form 4 filings provide a record of stock moves by corporate insiders.

Corning has hovered close to its recent highs, moving within a 52-week range of $37.31 to $113.99, data from Investing.com shows.

After Monday’s close, the stock traded near $113 in after-hours, according to MarketWatch data.

Corning is widely recognized by consumers for its Gorilla Glass in smartphones. Recently, however, traders have shifted focus, viewing the company more as a bet on connectivity hardware and fiber demand linked to massive computing infrastructure projects.

Meta’s deal with Corning extends to 2030 and involves boosting Corning’s production capabilities in North Carolina. Meta will serve as a key client at Corning’s Hickory cable facility, according to a Reuters report last week.

Still, the rally sets a high bar. Any slip in panel pricing, a drop in TV demand, or a slower-than-anticipated ramp-up in large data-center orders might weigh on a stock that’s already surged.

During the regular session, eyes will be on Corning to see if it can stay above the $110 mark after the 9:30 a.m. ET open and if it attempts to challenge the $113.99 peak again.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Crude oil price today: Brent steadies near $66 after a 4% slide as Iran talks loom
Previous Story

Crude oil price today: Brent steadies near $66 after a 4% slide as Iran talks loom

Lumentum stock jumps into earnings day as LITE traders brace for after-bell report
Next Story

Lumentum stock jumps into earnings day as LITE traders brace for after-bell report

Go toTop